Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Japanese study of intravenous or subcutaneous rituximab plus CHOP in previously untreated B-cell follicular lymphoma
jRCT2021200043Phase 3Active, not recruiting
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in follicular lymphoma (FL), sponsored by Nippon Zenyaku Kogyo Co., Ltd. Primary endpoint: Overall response rate. Started May 2021; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2021200043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200043.